中国PD-L1阳性食管鳞状细胞癌一线治疗中斯鲁利单抗联合化疗的成本效果分析数据表1

数据集获取（Figshare）

• 源站标题：DataSheet_1_Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.pdf
• DOI：10.3389/fimmu.2023.1172242.s001
• 发布日期：2023-05-04
• 文件数：1 个
• 文件总体积：1.66 MB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Cost-effectiveness_analysis_of_serplulimab_plus_chemotherapy_in_the_first-line_treatment_for_PD-L1-positive_esophageal_squamous_cell_carcinoma_in_China_pdf/22757888

命令行下载

curl -L -o "DataSheet_1_Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carci.pdf" "https://ndownloader.figshare.com/files/40436561"

文件清单

• DataSheet_1_Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carci.pdf（1.66 MB）

文件总体积 1.66 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveThe ASTRUM-007 trial (NCT03958890) demonstrated that serplulimab plus chemotherapy administered every 2-week significantly improved progression-free and overall survival in patients with previously untreated, programmed death-ligand 1 (PD-L1) positive advanced esophageal squamous-cell carcinoma (ESCC). This study was aimed to investigate the cost-effectiveness of serplulimab plus chemotherapy in the first-line treatment of PD-L1-positive advanced ESCC.
MethodsA partitioned survival model with a 2-week cycle and a 10-year time horizon was constructed from the Chinese healthcare system perspective. The survival data, direct medical costs and utilities were derived from the ASTRUM-007 trial, YAOZHI database and published sources. Total costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. Scenario, one-way and probabilistic sensitivity analyses were performed to assess the uncertainty around model parameters.
ResultsCompared with chemotherapy, serplulimab plus chemotherapy provided additional 0.27 QALYs with an incremental cost of $33,460.86, which had an ICER of $124,483.07 per QALY. The subgroup analyses revealed that the ICERs of serplulimab plus chemotherapy were $134,637.42 and $105,589.71 in advanced ESCC patients with 1 ≤ CPS Serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive advanced ESCC might not be cost-effective in China.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2023.1172242.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Cost-effectiveness_analysis_of_serplulimab_plus_chemotherapy_in_the_first-line_treatment_for_PD-L1-positive_esophageal_squamous_cell_carcinoma_in_China_pdf/22757888）。